SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

American Renal Associates Holdings, Inc. – ‘10-K’ for 12/31/16 – ‘R23’

On:  Wednesday, 3/8/17, at 5:31pm ET   ·   For:  12/31/16   ·   Accession #:  1498068-17-12   ·   File #:  1-37751

Previous ‘10-K’:  None   ·   Next:  ‘10-K’ on 3/6/18 for 12/31/17   ·   Latest:  ‘10-K’ on 3/16/20 for 12/31/19   ·   4 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 3/08/17  American Renal Assocs Holdin… Inc 10-K       12/31/16   97:12M

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   2.15M 
 2: EX-21.1     Subsidiaries List                                   HTML    106K 
 3: EX-23.1     Consent of Experts or Counsel                       HTML     26K 
 4: EX-31.1     Certification -- §302 - SOA'02                      HTML     34K 
 5: EX-31.2     Certification -- §302 - SOA'02                      HTML     33K 
 6: EX-32.1     Certification -- §906 - SOA'02                      HTML     30K 
 7: EX-32.2     Certification -- §906 - SOA'02                      HTML     29K 
14: R1          Document and Entity Information                     HTML     53K 
15: R2          Consolidated Balance Sheets                         HTML    119K 
16: R3          Consolidated Balance Sheets (Parenthetical)         HTML     44K 
17: R4          Consolidated Statements of Operations               HTML     94K 
18: R5          Consolidated Statements of Comprehensive Income     HTML     41K 
19: R6          Consolidated Statements of Changes in Equity        HTML    144K 
20: R7          Consolidated Statements of Changes in Equity        HTML     29K 
                (Parenthetical)                                                  
21: R8          Consolidated Statements of Cash Flows               HTML    156K 
22: R9          Presentation                                        HTML     30K 
23: R10         Summary of Significant Accounting Policies          HTML     85K 
24: R11         Initial Public Offering                             HTML     43K 
25: R12         Acquisitions                                        HTML     53K 
26: R13         Fair Value of Financial Instruments                 HTML    114K 
27: R14         Property and Equipment                              HTML     44K 
28: R15         Intangible Assets and Goodwill                      HTML     73K 
29: R16         Accrued Expenses and Other Current Liabilities      HTML     51K 
30: R17         Variable Interest Entities                          HTML     35K 
31: R18         Noncontrolling Interests Subject to Put Provisions  HTML     32K 
32: R19         Changes in Ownership Interest in Consolidated       HTML     50K 
                Subsidiaries                                                     
33: R20         Debt                                                HTML     81K 
34: R21         Leases                                              HTML     65K 
35: R22         Income Taxes                                        HTML    118K 
36: R23         Earnings (Loss) Per Share                           HTML     91K 
37: R24         Equity                                              HTML     38K 
38: R25         Stock-Based Compensation                            HTML    142K 
39: R26         Related Party Transactions                          HTML     40K 
40: R27         Commitments and Contingencies                       HTML     34K 
41: R28         Certain Legal Matters                               HTML     38K 
42: R29         Employee Benefit Plan                               HTML     29K 
43: R30         Concentrations                                      HTML     31K 
44: R31         Selected Quarterly Financial Data (Unaudited)       HTML    106K 
45: R32         Summary of Significant Accounting Policies          HTML    114K 
                (Policies)                                                       
46: R33         Summary of Significant Accounting Policies          HTML     30K 
                (Tables)                                                         
47: R34         Acquisitions (Tables)                               HTML     42K 
48: R35         Fair Value of Financial Instruments (Tables)        HTML    106K 
49: R36         Property and Equipment (Tables)                     HTML     41K 
50: R37         Intangible Assets and Goodwill (Tables)             HTML     72K 
51: R38         Accrued Expenses and Other Current Liabilities      HTML     52K 
                (Tables)                                                         
52: R39         Changes in Ownership Interest in Consolidated       HTML     51K 
                Subsidiaries (Tables)                                            
53: R40         Debt (Tables)                                       HTML     74K 
54: R41         Leases (Tables)                                     HTML     60K 
55: R42         Income Taxes (Tables)                               HTML    118K 
56: R43         Earnings (Loss) Per Share (Tables)                  HTML     88K 
57: R44         Stock-Based Compensation (Tables)                   HTML    126K 
58: R45         Selected Quarterly Financial Data (Unaudited) (     HTML    105K 
                Tables)                                                          
59: R46         Presentation (Details)                              HTML     37K 
60: R47         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     36K 
                Accounts Receivable (Details)                                    
61: R48         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     34K 
                Property and Equipment (Details)                                 
62: R49         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     30K 
                Amortizable Intangible Assets (Details)                          
63: R50         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     27K 
                Identified Non Amortizable Intangible Assets and                 
                Goodwill (Details)                                               
64: R51         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     39K 
                Impairment of Long Lived Assets (Details)                        
65: R52         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     39K 
                Recent Accounting Pronouncements (Details)                       
66: R53         Initial Public Offering (Details)                   HTML    126K 
67: R54         Acquisitions (Details)                              HTML     49K 
68: R55         Fair Value of Financial Instruments (Details)       HTML     79K 
69: R56         Property and Equipment (Details)                    HTML     48K 
70: R57         Intangible Assets and Goodwill (Details)            HTML     49K 
71: R58         Intangible Assets and Goodwill - Estimated annual   HTML     42K 
                amortization expense (Details)                                   
72: R59         INTANGIBLE ASSETS AND GOODWILL - Changes in the     HTML     33K 
                value of goodwilll (Details)                                     
73: R60         Accrued Expenses and Other Current Liabilities      HTML     46K 
                (Details)                                                        
74: R61         Variable Interest Entities (Details)                HTML     29K 
75: R62         Noncontrolling Interests Subject to Put Provisions  HTML     38K 
                (Details)                                                        
76: R63         Changes in Ownership Interest in Consolidated       HTML     44K 
                Subsidiaries (Details)                                           
77: R64         Debt (Details)                                      HTML     67K 
78: R65         Debt - Credit And Interest Rate Swap Agreements     HTML    106K 
                (Detail)                                                         
79: R66         Leases (Details)                                    HTML    102K 
80: R67         Income Taxes (Details)                              HTML     47K 
81: R68         Income Taxes - Significant components of deferred   HTML     66K 
                tax assets and liabilities (Details)                             
82: R69         INCOME TAXES - Reconciliation of the federal        HTML     49K 
                statutory rate (Details)                                         
83: R70         Earnings (Loss) Per Share (Details)                 HTML     68K 
84: R71         Equity (Details)                                    HTML     48K 
85: R72         STOCK-BASED COMPENSATION - Share Based              HTML     51K 
                Compensation Plans & Shares reserved (Details)                   
86: R73         STOCK BASED COMPENSATION - Equity Grants,           HTML     33K 
                Assumptions and Activity (Details)                               
87: R74         STOCK-BASED COMPENSATION - Weighted - average       HTML    101K 
                assumptions and stock option activity (Details)                  
88: R75         STOCK BASED COMPENSATION - Stock options and        HTML     38K 
                compensation costs (Details)                                     
89: R76         Related Party Transactions (Details)                HTML     80K 
90: R77         Commitments and Contingencies (Details)             HTML     29K 
91: R78         Certain Legal Matters (Details)                     HTML     32K 
92: R79         Employee Benefit Plan (Details)                     HTML     27K 
93: R80         Concentrations (Details)                            HTML     26K 
94: R81         Selected Quarterly Financial Data (Unaudited)       HTML     49K 
                (Details)                                                        
96: XML         IDEA XML File -- Filing Summary                      XML    171K 
95: EXCEL       IDEA Workbook of Financial Reports                  XLSX    105K 
 8: EX-101.INS  XBRL Instance -- ara-20161231                        XML   2.23M 
10: EX-101.CAL  XBRL Calculations -- ara-20161231_cal                XML    277K 
11: EX-101.DEF  XBRL Definitions -- ara-20161231_def                 XML    609K 
12: EX-101.LAB  XBRL Labels -- ara-20161231_lab                      XML   1.70M 
13: EX-101.PRE  XBRL Presentations -- ara-20161231_pre               XML   1.15M 
 9: EX-101.SCH  XBRL Schema -- ara-20161231                          XSD    198K 
97: ZIP         XBRL Zipped Folder -- 0001498068-17-000012-xbrl      Zip    202K

‘R23’   —   Earnings (Loss) Per Share

This is an IDEA Financial Report.  [ Alternative Formats ]

 
v3.7.0.1
EARNINGS (LOSS) PER SHARE
 12 Months Ended
EARNINGS (LOSS) PER SHARE  
EARNINGS (LOSS) PER SHARE

NOTE 15—EARNINGS (LOSS) PER SHARE

 

Basic earnings (loss) per share is computed by dividing net income (loss) attributable to American Renal Associates Holdings, Inc., net of the change in the difference between the estimated fair values of contractual noncontrolling interest put provisions and estimated fair values for accounting purposes of the related noncontrolling interests, by the weighted-average number of common shares outstanding during the applicable period. Diluted earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the applicable period, plus the dilutive effect of outstanding options, using the treasury stock method and the average market price of the Company’s common stock during the applicable period. Certain shares related to some of the Company’s outstanding stock options were excluded from the computation of diluted earnings per share because they were anti-dilutive in the periods presented, but could be dilutive in the future.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The Year Ended 

 

 

 

2016

    

2015

    

2014

 

Basic

 

 

  

 

 

  

 

 

  

 

Net income (loss)

 

$
(385)

 

$
18,845

 

$
16,197

 

Change in the difference between the estimated fair values of contractual noncontrolling interest put provisions and estimated fair values for accounting purposes of the related noncontrolling interests

 

 
(7,404)

 

 

 —

 

 

 —

 

Net income (loss) attributable to American Renal Associates Holdings, Inc. for basic earnings per share calculation

 

 
(7,789)

 

 
18,845

 

 
16,197

 

Weighted‑average common shares outstanding

 

 
28,118,673

 

 
22,153,451

 

 
21,930,398

 

Earnings (loss) per share, basic

 

$
(0.28)

 

$
0.85

 

$
0.74

 

Diluted

 

 

  

 

 

  

 

 

  

 

Net income (loss)

 

$
(385)

 

$
18,845

 

$
16,197

 

Change in the difference between the estimated fair values of contractual noncontrolling interest put provisions and estimated fair values for accounting purposes of the related noncontrolling interests

 

 
(7,404)

 

 

 —

 

 

 —

 

Net income (loss) attributable to American Renal Associates Holdings, Inc. for diluted earnings per share calculation

 

 
(7,789)

 

 
18,845

 

 
16,197

 

Weighted‑average common shares outstanding

 

 
28,118,673

 

 
22,153,451

 

 
21,930,398

 

Weighted-average effect of dilutive securities:

 

 

 

 

 

 

 

 

 

 

Effect of assumed exercise of stock options

 

 

 —

 

 
554,423

 

 
402,489

 

Weighted‑average common shares outstanding, assuming dilution

 

 
28,118,673

 

 
22,707,874

 

 
22,332,887

 

Earnings (loss) per share, diluted

 

$
(0.28)

 

$
0.83

 

$
0.73

 

Outstanding options excluded as impact would be antidilutive

 

 
572,097

 

 
58,899

 

 
110,454

 

 

Dates Referenced Herein

This ‘10-K’ Filing    Date    Other Filings
Filed on:3/8/17None on these Dates
For Period end:12/31/16
 List all Filings 

4 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/07/17  SEC                               UPLOAD10/07/17    1:35K  American Renal Assocs Holdin… Inc
 7/20/17  SEC                               UPLOAD10/07/17    1:137K American Renal Assocs Holdin… Inc
 6/26/17  SEC                               UPLOAD10/07/17    1:139K American Renal Assocs Holdin… Inc
 5/25/17  SEC                               UPLOAD10/07/17    1:139K American Renal Assocs Holdin… Inc
↑Top
Filing Submission 0001498068-17-000012   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Mon., May 6, 2:13:43.2am ET